Our aim was to evaluate clinical outcomes of first-line pembrolizumab plus pemetrexed-carboplatin in a real-world clinical setting for patients with good performance status (Eastern Cooperative Oncology Group performance status [ECOG PS] of 0 or 1) and tumor characteristics similar to those in KEYNOTE-189, namely, metastatic nonsquamous NSCLC without EGFR or ALK genomic aberrations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.